Page 5 - ஜெசிகா ப்ரூ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜெசிகா ப்ரூ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜெசிகா ப்ரூ Today - Breaking & Trending Today

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

Share this article
NEW YORK, June 1, 2021 /PRNewswire/
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic.
Inderpal is a seasoned legal executive, having spent 20 years in-house, advising several of the world s largest life sciences companies. As such, he brings to Immunic extensive legal knowledge related to clinical development, operations, regulatory affairs, and commercialization, stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. We welcome Inderpal to the management team and look forward to his guidance as we continue to advance our pipeline of selective oral immunology the ....

Baden Wüberg , Edna Kaplan , Paula Schwartz , Jessica Breu , Deutschland Gmb , Daniel Vitt , Sandoz International Gmb , Rx Communications Group , Exchange Commission , Business School In Fontainebleau , Merck Kga , Pfizer Inc , Merck Kgaa , Europe At Biogen Idec International Gmb , Law At Johannes Gutenberg University In Mainz , University Of Mannheim , Immunic Inc , Inderpal Singh , General Counsel , Chief Executive Officer , Sandoz International Gmbh , Global Legal Head , Global Manufacturing , Regional Counsel , Middle East , Independent States ,

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

Share this article
NEW YORK, May 6, 2021 /PRNewswire/
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2021 and highlighted recent activity.
Our clinical program activities have continued unabated, with significant progress having recently been achieved for our lead asset, selective oral DHODH inhibitor, IMU-838, stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. Last month, we announced key interim data from our phase 2 EMPhASIS Cohort 2 sub-trial of IMU-838 in patients with relapsing-remitting multiple sclerosis (RRMS), confirming 30 mg as the most appropriate dose for our envisaged phase 3 program. We will now move directly to the filing of an Investigational New Drug (IND) application in the United States and are curren ....

United States , Paula Schwartz , Edna Kaplan , Jessica Breu , Daniel Vitt , Rx Communications Group , Prnewswire Immunic Inc , Daiichi Sankyo Co Ltd , Exchange Commission , Development Rd Expenses , Ethics Committee , European Medicines Agency , Immunic Inc , Chief Executive Officer , Investigational New Drug , Cash Equivalents , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Consolidated Statements , ஒன்றுபட்டது மாநிலங்களில் , பால ஸ்க்வார்ட்ஸ் , எட்னா கபிலன் , ஜெசிகா ப்ரூ , டேனியல் விட் , ர்க்ஸ் தகவல்தொடர்புகள் குழு ,

Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment. ....

United States , Edna Kaplan , Paula Schwartz , Jessica Breu , Andreas Muehler , Daniel Vitt , Drug Administration , Rx Communications Group , Prnewswire Immunic Inc , Exchange Commission , European Medicines Agency , Immunic Inc , Investigational New Drug , Chief Medical Officer , Chief Executive Officer , Private Securities Litigation Reform Act , Annual Report , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , எட்னா கபிலன் , பால ஸ்க்வார்ட்ஸ் , ஜெசிகா ப்ரூ , டேனியல் விட் , ர்க்ஸ் தகவல்தொடர்புகள் குழு , பரிமாற்றம் தரகு , தலைமை மருத்துவ அதிகாரி ,

DGAP-News: Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection

(0)
DGAP-News: Immunic, Inc.
/ Key word(s): Study results
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838 s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
15.04.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838 s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
- Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Combination with Existing 30 and 45 mg Dose Data, Establishes Clear Dose-Response Relationship for IMU-838 -
- Totality of Data Clearly Supports Decision that 30 mg Once Daily Dose of IMU-838 Will Now Be Targeted for Phase 3 Development in Relapsing-Remitting Multiple Sclerosis - ....

United States , Edna Kaplan , Paula Schwartz , Jessica Breu , Andreas Muehler , Daniel Vitt , Program Expected To Start , Drug Administration , Rx Communications Group , Distribution Services , Exchange Commission , European Medicines Agency , Immunic Inc , Cohort Confirms , Relapsing Remitting Multiple Sclerosis , Supports Phase , Interim Analysis , Dose Data , Establishes Clear Dose Response Relationship , Data Clearly Supports Decision , Once Daily Dose , Now Be Targeted , Previously Announced , Second Half , Investigational New Drug , Chief Medical Officer ,

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
vom 13.04.2021, 12:30 Uhr
Bild: pixabay.com
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
13.04.2021 / 12:30
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, investor and industry conferences in April:
- April 17-22:
2021 Virtual American Academy of Neurology (AAN) Annual Meeting. Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, will present the full data set from Immunic s phase 2 ....

United States , Edna Kaplan , Paula Schwartz , Jessica Breu , Robertj Fox , Daniel Vitt , Mellen Center , Rx Communications Group , Distribution Services , Exchange Commission , Neurologic Institute , Virtual American Academy Of Neurology , Program Number , Immunic Inc , American Academy , Staff Neurologist , Multiple Sclerosis , Cleveland Clinic , Selective Oral , Vidofludimus Calcium , Relapsing Remitting Multiple Sclerosis , Placebo Controlled Phase , Riley Neuroscience , Chief Executive Officer , German Corona Showcase , Private Securities Litigation Reform Act ,